Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) and MedImmune, Inc. (Nasdaq: MEDI) announced the preliminary results of an open-label Phase I clinical study of IPI-504 in patients with Gleevec®-resistant metastatic gastrointestinal stromal tumors (GIST).
A proprietary small molecule inhibitor of Heat Shock Protein 90 (Hsp90) that is being jointly developed by Infinity and MedImmune, IPI-504 is Infinity's lead oncology drug candidate.
The still ongoing open-label, dose-escalation Phase I trial of IPI-504 is being conducted at the Dana-Farber Cancer Institute in Boston, Mass. under the direction of George Demetri MD, director of the Ludwig Center at Dana-Farber/Harvard and director of Dana-Farber's Center for Sarcoma and Bone Oncology.
IPI-504 has been well-tolerated to date at all dose levels tested, and a maximum tolerated dose has not yet been identified. Investigators have observed evidence of biological activity for IPI-504 using positron emission tomography imaging, or PET.
Find more details of the clinical data from the full press release.
[Photo Credit: American Cancer Society]
Comment Preview